S&P 500   3,426.92 (-1.63%)
DOW   28,195.42 (-1.44%)
QQQ   284.89 (-1.25%)
AAPL   116.60 (-2.03%)
MSFT   215.68 (-1.81%)
FB   262.36 (-1.34%)
GOOGL   1,534.71 (-2.10%)
AMZN   3,220.00 (-1.61%)
TSLA   433.78 (-1.34%)
NVDA   540.71 (-2.13%)
BABA   305.75 (-0.51%)
CGC   19.85 (+11.77%)
GE   7.32 (+0.41%)
MU   52.64 (+2.00%)
AMD   82.30 (-1.05%)
T   26.90 (-1.57%)
F   7.59 (-1.04%)
ACB   4.65 (+15.67%)
GILD   60.55 (-2.34%)
NFLX   532.87 (+0.39%)
BA   167.30 (-0.03%)
BAC   23.69 (-2.27%)
DIS   124.28 (-2.00%)
S&P 500   3,426.92 (-1.63%)
DOW   28,195.42 (-1.44%)
QQQ   284.89 (-1.25%)
AAPL   116.60 (-2.03%)
MSFT   215.68 (-1.81%)
FB   262.36 (-1.34%)
GOOGL   1,534.71 (-2.10%)
AMZN   3,220.00 (-1.61%)
TSLA   433.78 (-1.34%)
NVDA   540.71 (-2.13%)
BABA   305.75 (-0.51%)
CGC   19.85 (+11.77%)
GE   7.32 (+0.41%)
MU   52.64 (+2.00%)
AMD   82.30 (-1.05%)
T   26.90 (-1.57%)
F   7.59 (-1.04%)
ACB   4.65 (+15.67%)
GILD   60.55 (-2.34%)
NFLX   532.87 (+0.39%)
BA   167.30 (-0.03%)
BAC   23.69 (-2.27%)
DIS   124.28 (-2.00%)
S&P 500   3,426.92 (-1.63%)
DOW   28,195.42 (-1.44%)
QQQ   284.89 (-1.25%)
AAPL   116.60 (-2.03%)
MSFT   215.68 (-1.81%)
FB   262.36 (-1.34%)
GOOGL   1,534.71 (-2.10%)
AMZN   3,220.00 (-1.61%)
TSLA   433.78 (-1.34%)
NVDA   540.71 (-2.13%)
BABA   305.75 (-0.51%)
CGC   19.85 (+11.77%)
GE   7.32 (+0.41%)
MU   52.64 (+2.00%)
AMD   82.30 (-1.05%)
T   26.90 (-1.57%)
F   7.59 (-1.04%)
ACB   4.65 (+15.67%)
GILD   60.55 (-2.34%)
NFLX   532.87 (+0.39%)
BA   167.30 (-0.03%)
BAC   23.69 (-2.27%)
DIS   124.28 (-2.00%)
S&P 500   3,426.92 (-1.63%)
DOW   28,195.42 (-1.44%)
QQQ   284.89 (-1.25%)
AAPL   116.60 (-2.03%)
MSFT   215.68 (-1.81%)
FB   262.36 (-1.34%)
GOOGL   1,534.71 (-2.10%)
AMZN   3,220.00 (-1.61%)
TSLA   433.78 (-1.34%)
NVDA   540.71 (-2.13%)
BABA   305.75 (-0.51%)
CGC   19.85 (+11.77%)
GE   7.32 (+0.41%)
MU   52.64 (+2.00%)
AMD   82.30 (-1.05%)
T   26.90 (-1.57%)
F   7.59 (-1.04%)
ACB   4.65 (+15.67%)
GILD   60.55 (-2.34%)
NFLX   532.87 (+0.39%)
BA   167.30 (-0.03%)
BAC   23.69 (-2.27%)
DIS   124.28 (-2.00%)
Log in

7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle in 2020

Posted on Wednesday, October 7th, 2020 by MarketBeat Staff
7 Stocks That May Provide the Real Solution to The Coronavirus PuzzleOctober 2, 2020, may not rank as one of those “where were you when” moments. But when news broke that the President of the United States and the First Lady tested positive for the novel coronavirus, there was certainly a sense that we were living through a historical moment (as if we already were not).

Over the following days, several biotech and pharmaceutical companies took the headlines. However, these weren’t the vaccine stocks that investors have committed to memory. These were companies that are leading the race for antiviral therapeutics.

And with a very high profile proof of concept, therapeutics may have had their moment. It’s far too early to say whether these drugs truly carry the answer. But from the outset of the pandemic, there has been a feeling that therapeutics may carry the ultimate solution to neutralizing the most severe effects of the novel coronavirus.

As you might expect, there is no shortage of companies in the therapeutic discussion. In this special presentation, we’re highlighting seven companies that you should be paying close attention to. If therapeutics nudge ahead of a vaccine, these stocks are likely to make strong upward moves.

#1 - Gilead Sciences (NASDAQ:GILD)

Gilead Sciences logo

Gilead Sciences (NASDAQ:GILD) is in the headlines for its therapeutic antiviral treatment called remdesivir. Gilead stock is essentially flat for the year, but investors have been on quite the ride. In the six weeks from the onset of the extreme mitigation efforts to the end of April, GILD stock charged ahead by 22%. But it’s since given up most of those gains.

Part of the reason for this is that the race for a vaccine took center stage, and it pulled investor attention away from therapeutics. And also, remdesivir was not seen as being an all-in-one solution for Covid-19. But if there’s anything the President’s treatment is showing it’s that remdesivir may still have a role to play as one of several therapeutic solutions.

But investors should be attracted to Gilead for other reasons. The company has an established pipeline that is not dependent on treating the novel coronavirus. And it also pays a respectable dividend.

About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. Read More 

Current Price: $60.55
Consensus Rating: Hold
Ratings Breakdown: 10 Buy Ratings, 15 Hold Ratings, 2 Sell Ratings.
Consensus Price Target: $78.93 (30.3% Upside)



#2 - AbbVie (NYSE:ABBV)

AbbVie logo

One thing that scientists are discovering is that established antivirals are proving to have some effect on the novel coronavirus. That’s the case with AbbVie (NYSE:ABBV). The company’s HIV treatment, Kaletra (also called Aluvia) is being used in China to treat pneumonia that patients experience due to the coronavirus. Kaletra has not been approved as an approved treatment for the virus, but it has a history of being effective.

In 2004, a clinical study proved that the drug was an effective treatment for SARS (Sudden Acute Respiratory Syndrome). AbbVie is literally putting its own money into the game. The company has donated nearly $1.5 million worth of the drug to China. If the drug is proven to be effective over a large patient population, Kaletra could be a billion-dollar drug for AbbVie.

ABBV stock is down about 3% for the year, which makes this a nice buying opportunity, particularly when you consider that you’re getting a company with an established pipeline and a reliable dividend confirmed by its membership in the exclusive Dividend Aristocrat club.

About AbbVie
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. Read More 

Current Price: $84.32
Consensus Rating: Buy
Ratings Breakdown: 13 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $108.63 (28.8% Upside)



#3 - Regeneron (NASDAQ:REGN)

Regeneron Pharmaceuticals logo

Regeneron (NASDAQ:REGN) is making news for its part in treating President Trump. However, that is only part of the story. Regeneron first made news by announcing it was working with Sanofi (NYSE:SNY) to test Kevzara – which is used to treat rheumatoid arthritis – as a potential treatment for boosting the immune system of Covid-19 patients. Unfortunately, the companies experienced disappointing results in its Phase 2 trial.

However, Regeneron was already working on a separate project. This was the “cocktail” that President Trump received. The antiviral cocktail, REGN-COV2, only began clinical trials in June. So even though President Trump’s initial immune response appears favorable, it’s far too early to tell if this treatment will receive FDA approval. Nevertheless, the company is getting more requests via the FDA’s “compassionate use” authorization.

REGN stock is up 56% for the year but is only up 3% on news of President Trump’s treatment. This is consistent with the company’s history in which the company has shown a strong average annual revenue growth of 22%, but it has not translated into the company’s stock price.

About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. Read More 

Current Price: $583.45
Consensus Rating: Buy
Ratings Breakdown: 15 Buy Ratings, 9 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $622.13 (6.6% Upside)



#4 - Eli Lilly (NYSE:LLY)

Eli Lilly And Co logo

On the heels of Regeneron’s drug cocktail, Eli Lilly (NYSE:LLY) is applying for an emergency use authorization (EUA) for its coronavirus antibody treatment. The company’s experimental antibody, Y-CoV555 is currently in the trial stage. However, the company has documented that the treatment is reducing the number of patients who need to be hospitalized or seek emergency room treatment for moderate Covid-19 symptoms. The antiviral, which is administered through an IV, is said to be similar to Regeneron’s cocktail.

Eli Lilly has a separate rheumatoid arthritis drug, baricitinib, which it is developing in a partnership with Roche (OTCMKTS:RHHVF). This drug has been tested in combination with Gilead’s remdesivir to speed the recovery of Covid-19 patients.

Like several of the company’s in this presentation, there is more to like about Eli Lilly for more than just its work on the Covid-19 front. The company has a drug, tirzepatide, in its pipeline. The drug is in a late-stage (Phase 3) trial for the treatment of diabetes, obesity, and cardiovascular outcomes. One analyst told Barron’s that the drug could deliver $3.7 billion of sales by 2025.

LLY stock is up almost 12% for the year. Investors can also collect a nice dividend for their investment.

About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. Read More 

Current Price: $142.73
Consensus Rating: Buy
Ratings Breakdown: 9 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $170.75 (19.6% Upside)



#5 - Co-Diagnostics (NASDAQ:CODX)

Co-Diagnostics logo

Co-Diagnostics (NASDAQ:CODX) is one of the small-cap stocks that is rewarding investors in 2020. The keyword is testing. Co-Diagnostics has a rapid response test for the novel coronavirus that has been proven to deliver fewer false positives. The kit is also proving effective at catching mutations of the virus.

The stock has been surging since the FDA granted the test kit emergency use authorization in April. Co-Diagnostics was also the first U.S. company to get approval for its test kit from the European Union.

There is a sense that CODX stock may have priced in all of the good news. The stock is down over 50% since August. However, the stock is up 24% in the last month. This suggests that investors are buying into the notion that a vaccine won’t be delivered until early next year at the earliest. If that is the case, the need for testing will remain one of the key strategies for tracking the virus.

About Co-Diagnostics
Co-Diagnostics, Inc, a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.

Current Price: $13.64
Consensus Rating: Buy
Ratings Breakdown: 2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $31.50 (130.9% Upside)



#6 - Humanigen (NYSE:HGEN)

Humanigen logo

Humanigen (NYSE:HGEN) is a small-cap that may be flying under your radar. It shouldn’t be anymore. As scientists have come to learn more about the novel coronavirus, it is clear that it is important to avoid patients having a cytokine storm. This is basically the body having an aggressive inflammatory response to the novel coronavirus.

Humanigen has a drug candidate, lenzilumab, which is focused on preventing such events from happening. With President Trump’s diagnosis putting cytokine storm in the headlines, the company is initiating a public stock offering of 8 million shares of common stock. The offering is being underwritten by JP Morgan Chase (NYSE:JPM) and Jefferies (NYSE:JEF). The company says it will use the funds, in part, to support the manufacturing, product, and commercial preparation of the drug.

HGEN stock is up over 500% for the year but was up even higher. In early July, the stock was up over 1,000%. It’s obviously come down with more talk of a vaccine, but the stock is up nearly 50% in the last month.

About Humanigen
Humanigen, Inc, a biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase I/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia. Read More 

Current Price: $13.50
Consensus Rating: Buy
Ratings Breakdown: 1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $25.00 (85.2% Upside)



#7 - ChromaDex (NASDAQ:CDXC)

Chromadex logo

We conclude this presentation by looking at ChromaDex (NASDAQ:CDXC). This small-cap is up 20% for the year. Although it hasn’t been immune from the ups and downs of the market, CDXC has been less volatile than other biotech stocks.

One of the known risk groups for the novel coronavirus is the nation’s senior citizens, particularly those over the age of 70. Scientists have long looked at the role of nutrition in our ability to fight off viruses. ChromaDex is involved in the development of aging-related neutraceuticals. While the company is not a pure-play on the novel coronavirus, it has recently released the results of a study that shows how patients that were taking its nutritional protocol in addition to the standard of care saw a nearly 30% reduced recovery time from Covid-19.

One of the nice things about the company’s flagship product, TRU NIAGEN, is that it has significant intellectual property (IP) protection. This means that the company has little to no risk of having its product suffer patent infringement.

About Chromadex
ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. Read More 

Current Price: $4.94
Consensus Rating: Buy
Ratings Breakdown: 3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $7.67 (55.2% Upside)

 

The world is waiting to return to normal. There’s nothing wrong with that. It’s simply human nature. We were meant to be social beings. If we’re realistic, we know that the novel coronavirus is likely to be around for a long time.

However, the good news is that the best and brightest scientists know more about the virus. This is allowing them to confirm some suspicions. It also means that maybe all of our efforts to keep our distance have provided the time needed for companies to create new pathways to successful treatment.

And this is creating a tremendous opportunity for investors who are paying attention. Investing in these seven stocks is one way to ensure you’re taking advantage of it.

One thing that we can be extremely proud of is the way many of our nation’s leading biotech companies are working together to find solutions to this virus. Use your MarketBeat subscription to get alerts on breaking news surrounding these and other companies on your watch list.

7 Semiconductor Stocks to Power Your Portfolio

Semiconductor stocks are thought of as cyclical stocks. However as technology continues to evolve, the cycles for semiconductors have become almost indiscernible. And for the last 18 months, semiconductor stocks have been some of the most volatile stocks.

But the iShares PHLX Semiconductor ETF (NASDAQ:SOXX) is up nearly 17% (16.8%) in 2020. That far outpaces the S&P 500. And this is on the heels of 2019 when the normally “boring” index surged over 60%.

What are the catalysts for semiconductor stocks? At this point, the better question may be what isn’t a catalyst for this group. The 5G buildout looks to finally be underway despite the pandemic. Data centers keep on growing, new gaming consoles will be out later this year, and work from anywhere will continue to be the reality for many Americans.

Each of these segments will define the semiconductor industry for at least the rest of this year. And are likely to continue to dominate our national conversation long after the pandemic is over. But those aren’t the only catalysts. Online learning is going to increase in importance. And that means students will need the laptops and tablets that are capable of handling the speed and processing power needed for remote learning. And there’s still time for you to profit from this growing sector. In this presentation, we’ve identified seven of the best semiconductor stocks that still offer good growth opportunities.

View the "7 Semiconductor Stocks to Power Your Portfolio" Here.






Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.